0
     

Report Added
Report already added
Reflux Esophagitis (Gastroesophageal Reflux Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Reflux Esophagitis (Gastroesophageal Reflux Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 9, 13, 4 and 5 respectively.

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
Addpharma Inc
Ahn-Gook Pharmaceutical Co Ltd
CalyGene Biotechnology Inc
Cancer Advances Inc
Changchun Serene Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp
Cinclus Pharma AG
Daewoong Co Ltd
Eisai Co Ltd
EsoCap AG
Hana Pharm Co Ltd
Hanmi Pharmaceuticals Co Ltd
HK inno.N Corp
Ilyang Pharmaceutical Co Ltd
ISOThrive Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Korea Pharma Co Ltd
Korea United Pharm Inc
Onconic Therapeutics Co Ltd
RaQualia Pharma Inc
Renexxion LLC
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
Trio Medicines Ltd
Xiamen Encheng Pharmaceutical Co Ltd
XuanZhu Biological Technology Co Ltd
Yooyoung Pharm Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles
AD-206 - Drug Profile
Product Description
Mechanism Of Action
AD-212 - Drug Profile
Product Description
Mechanism Of Action
AD-213 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AD-214 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AG-1813 - Drug Profile
Product Description
Mechanism Of Action
azeloprazole sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
ceclazepide - Drug Profile
Product Description
Mechanism Of Action
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
CJ-30065 - Drug Profile
Product Description
Mechanism Of Action
CJ-30076 - Drug Profile
Product Description
Mechanism Of Action
CJ-30077 - Drug Profile
Product Description
Mechanism Of Action
CJ-30078 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CKD-382 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dexlansoprazole DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profile
Product Description
Mechanism Of Action
esomeprazole - Drug Profile
Product Description
Mechanism Of Action
History of Events
esomeprazole - Drug Profile
Product Description
Mechanism Of Action
History of Events
fexuprazan - Drug Profile
Product Description
Mechanism Of Action
History of Events
G-17DT - Drug Profile
Product Description
Mechanism Of Action
History of Events
ilaprazole DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
INC-005 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ISOT-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IYHCR-17 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JP-1366 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KBP-3571 - Drug Profile
Product Description
Mechanism Of Action
History of Events
konolazan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
KP-201 - Drug Profile
Product Description
Mechanism Of Action
lemborexant - Drug Profile
Product Description
Mechanism Of Action
History of Events
linaprazan glurate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibodies to Inhibit BMP2 and BMP4 for Barretts Esophagus - Drug Profile
Product Description
Mechanism Of Action
History of Events
naronapride - Drug Profile
Product Description
Mechanism Of Action
History of Events
netazepide - Drug Profile
Product Description
Mechanism Of Action
History of Events
pantoprazole DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
PTBC - Drug Profile
Product Description
Mechanism Of Action
SOCC-2 - Drug Profile
Product Description
Mechanism Of Action
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
History of Events
UI-049 - Drug Profile
Product Description
Mechanism Of Action
UI-058 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vonoprazan fumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
XY-066 - Drug Profile
Product Description
Mechanism Of Action
YHC-1139 - Drug Profile
Product Description
Mechanism Of Action
YPI-009 - Drug Profile
Product Description
Mechanism Of Action
YPI-011 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones
Featured News & Press Releases
Mar 14, 2022: Phathom Pharmaceuticals submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
Mar 07, 2022: Announcement of Luoxin Pharmaceutical on the approval of Tigola raw tablets to carry out clinical trials for new indications
Feb 21, 2022: HK inno.N predicts global success of K-Cab based on evidence
Feb 11, 2022: Regulator OKs inno. N's orally disintegrating tablet formulation for K-CAB
Feb 09, 2022: Phathom Pharmaceuticals announces positive topline results from phase 2 trial evaluating vonoprazan for non-erosive gastroesophageal reflux disease (NERD)
Oct 07, 2021: Entering China's tens of billions of acid suppression market, Shanghai Pharmaceuticals introduced blockbuster new drugs for RMB 690 million
Sep 27, 2021: Phathom Pharmaceuticals announces results from VONO-103, a phase 1 study evaluating gastric acid inhibition of Vonoprazan and Lansoprazole (PREVACID)
Sep 06, 2021: Cinclus Pharma receives approval of the International Nonproprietary Name (INN) linaprazan glurate for its lead drug candidate for the treatment of GERD
Aug 18, 2021: Cinclus Pharma announces the first patient randomized in the Phase II study for X842 in GERD
Mar 22, 2021: Application for manufacturing and marketing approval for orally disintegrating tablets of "Takecab Tablets", a therapeutic agent for acid-related diseases
Feb 01, 2021: Gastroesophageal reflux disease new drug K-Cab, launches in China
Dec 30, 2020: Daewoong Pharmaceutical's new drug for gastroesophageal reflux disease, “Peksuprazan,” approved for phase 3 in China
Dec 14, 2020: Phathom Pharmaceuticals announces plans to initiate vonoprazan development program in non-erosive reflux disease (NERD)
Nov 23, 2020: Korea's new drug, K-Cap, expands its entry into Asia
Nov 06, 2020: Daewoong Pharmaceutical announces publication of novel P-CAB fexuprazan phase 1 bridging study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Addpharma Inc, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by CalyGene Biotechnology Inc, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cancer Advances Inc, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Changchun Serene Pharmaceutical Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cinclus Pharma AG, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by EsoCap AG, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Hana Pharm Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by HK inno.N Corp, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by ISOThrive Inc, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Korea Pharma Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Korea United Pharm Inc, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Onconic Therapeutics Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Renexxion LLC, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Trio Medicines Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Xiamen Encheng Pharmaceutical Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by XuanZhu Biological Technology Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuhan Corp, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yungjin Pharm Co Ltd, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, 2022 (Contd..1)
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, 2022 (Contd..2)
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, 2022
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, 2022 (Contd..1)

List of Figures
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Reflux Esophagitis (Gastroesophageal Reflux Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Imaging Systems: Global Markets

Dental Imaging Systems: Global Markets

Telecom operators’ strategies in the health market

Telecom operators’ strategies in the health market

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline